Robyn Hunter insider trades
Open-market stock purchases and sales by Robyn Hunter, Director at Tenax Therapeutics, Inc, from SEC Form 4 filings since Nov 23, 2018.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +185%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jan 9, 2026 | TENX Tenax Therapeutics, Inc | Bought (not open market) | — |